Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
Phase 2
Completed
- Conditions
- Sjogren Syndrome
- Registration Number
- JPRN-jRCT2080224883
- Lead Sponsor
- ovartis Pharma. K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 260
Inclusion Criteria
Classification of Sjogren's Syndrome according to ACR/EULAR 2016 criteria (Shiboski et al 2017)
Exclusion Criteria
Sjogren's Syndrome overlap syndromes where another autoimmune rheumatic disease constitutes the principle illness
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy<br>Cohort 1 - Change in EULAR Sjogren Syndrome Disease Activity Index (ESSDAI) score<br>Cohort 2 - Change in EULAR Sjogren Syndrome Patient Reported Index (ESSPRI) score
- Secondary Outcome Measures
Name Time Method